For B2B clients, quickly identifying a core product with high purity, stable supply, and compliant qualifications in the complex raw material market is often crucial to business success. Today, we focus on FBP sodium (sodium fructose-1,6-bisphosphate), a functional raw material that has garnered significant attention in the pharmaceutical and biological buffering fields. As a key intermediate in the glycolysis pathway, it not only holds a central position in classic drugs due to its efficient energy supply and antioxidant properties, but also demonstrates remarkable application potential in cutting-edge applications such as cell culture and biological reagents.
What is FBP sodium?
FBP sodium, short for D-fructose-1,6-bisphosphate trisodium salt, is a naturally occurring functional phosphate sugar compound in living organisms. As a key metabolic intermediate in glycolysis (the core pathway of glucose breakdown for energy), it occupies a pivotal position in energy metabolism and is a direct precursor to glyceraldehyde-3-phosphate and dihydroxyacetone phosphate. The FBP sodium molecule contains two high-energy phosphate bonds, which endow it with unique physiological activity.
To ensure product stability and ease of use, commercially available raw materials are usually available as a hydrated trisodium salt, appearing as a white or off-white powder with good water solubility. The core value of FBP sodium stems from its powerful cell-protective and metabolic regulatory functions. This characteristic makes it not only the core active ingredient in injectable fructose-1,6-bisphosphate sodium preparations, used clinically as an adjunct treatment for myocardial ischemia and brain injury, but also demonstrates broad application potential in the biopharmaceutical field.
What does FBP sodium do?
The mechanism of action of fructose-1,6-bisphosphate sodium (FBP sodium) mainly revolves around its regulation of cellular energy metabolism and its cellular protective functions. As a high-energy phosphate compound, it can directly enter the glycolysis pathway, bypassing the rate-limiting enzyme phosphofructokinase (PFK). Under energy-deficient conditions such as ischemia and hypoxia, it is rapidly utilized by cells as an exogenous substrate, thereby restoring the efficiency of anaerobic glycolysis and increasing intracellular ATP (adenosine triphosphate) production.
Furthermore, FBP sodium powder effectively maintains the structural integrity and permeability of the cell membrane by stabilizing the phospholipid bilayer and inhibiting oxygen-free radical-induced lipid peroxidation, reducing the leakage of intracellular enzymes and metabolites. Simultaneously, it can regulate intracellular pH, alleviate acidosis damage caused by lactic acid accumulation, and inhibit apoptosis signaling pathways triggered by calcium overload. Therefore, from an overall effect perspective, FBP sodium does not directly act on specific receptors but rather exerts its protective effect on ischemic and hypoxic tissues through multiple mechanisms, including improving the metabolic state of energy-deficient cells, stabilizing membrane structure, and antioxidation.
Is FBP sodium good for cardiovascular?
Yes, existing research and clinical applications have demonstrated that FBP sodium has significant protective and ameliorative effects on the cardiovascular system. Especially in pathological states such as myocardial ischemia and hypoxia, it plays a crucial role in metabolic support and cell protection. As a cardiovascular drug approved by the National Medical Products Administration, fructose diphosphate sodium injection is specifically indicated for improving angina pectoris, acute myocardial infarction, arrhythmia, and myocardial ischemia associated with heart failure in patients with coronary heart disease.
Its core mechanism lies in the fact that exogenous FBP sodium can bypass the rate-limiting step in the glycolysis pathway, directly providing high-energy substrates to ischemic cardiomyocytes, significantly increasing intracellular ATP and phosphocreatine levels. This not only directly provides energy to dying cardiomyocytes to maintain their basic structure and function, but also reduces cell damage caused by ischemia-reperfusion by stabilizing the cardiomyocyte membrane and inhibiting the release of harmful oxygen free radicals and histamine.
how long for FBP to take effect?
The onset time of fructose-1,6-bisphosphate sodium (FBP sodium) varies depending on the route of administration, indications, and individual patient differences. Intravenous administration provides the most rapid onset of action. Pharmacokinetic data support this rapid onset: in healthy volunteers, peak plasma concentrations are reached within 5 minutes of intravenous infusion, and the plasma half-life is approximately 10–15 minutes, meaning the drug can rapidly distribute to ischemic tissues and exert its effect. This rapid onset of action is of significant clinical importance for patients with acute myocardial ischemia, myocardial infarction, and other acute and critical conditions.
Oral formulations, however, require gastrointestinal absorption and have a relatively slower onset of action, typically showing efficacy 1–2 weeks after administration, with peak plasma concentrations reaching approximately 51 minutes. For patients recovering from chronic heart failure, cardiomyopathy, or brain injury, continuous energy support is required for tissue repair, FBP often necessitating weeks to months of continuous use to achieve significant functional improvement. In general, intravenous administration is suitable for acute ischemic states requiring rapid intervention, while oral formulations are more suitable for long-term energy support and tissue repair therapy.
how much FBP trisodium salt per day?
The daily dosage of fructose-1,6-bisphosphate trisodium salt (FBP trisodium salt) varies depending on the route of administration, indication, and patient's specific condition, and must be determined under the guidance of a professional physician. Intravenous administration is the most commonly used method in clinical practice. The routine dosage of injectable fructose-1,6-bisphosphate sodium is 5–10 grams (calculated as FBP) per dose, administered via intravenous infusion or pump infusion. For acute and severe conditions such as acute myocardial infarction and myocardial ischemia, it is usually administered 1–2 times daily for 3–7 consecutive days, with the specific course of treatment determined based on the patient's condition.
The recommended dosage for oral formulations is relatively lower. In clinical studies, the commonly used regimen for oral fructose-1,6-bisphosphate sodium formulations (such as capsules and powders) is 1–2 grams per dose, 2–3 times daily, for a total daily dose of 2–6 grams. Due to limited oral bioavailability (approximately 10%–15%), this dosage is suitable for long-term metabolic support in patients with chronic heart failure, stable coronary artery disease, or those recovering from brain injury, and typically requires continuous administration for more than 4 weeks to achieve significant functional improvement.
Where to buy the best FBP sodium powder?
When selecting fructose-1,6-bisphosphate trisodium salt (FBP) as a raw material, please feel free to contact Healthkintai. Our FBP raw materials utilize mature enzymatic catalysis and crystallization processes, ensuring product purity ≥99%, meeting high pharmaceutical-grade standards. Each batch comes with a complete third-party certificate of account (COA), with heavy metal and solvent residues strictly controlled within limits. We can guarantee rapid delivery from gram-level samples to ton-level orders. Choosing us means not only choosing a high-purity core raw material, but also selecting a reliable partner for your formulation development and commercial production.Contact us at info@kintaibio.com.
